Covidien (NYSE: COV) today announced that one of its Pharmaceutical Products subsidiaries has acquired the licensing rights to drug candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE